research use only

Berzosertib (VE-822) ATR inhibitor

Name: Berzosertib (VE-822)
SKU: S7102
Availability: InStock
Rating: 5 (146 reviews)

Cat.No.S7102

Berzosertib (VE-822, VX970, M6620) is an ATR inhibitor with IC50 of 19 nM in HT29 cells.

Chemical Structure

Molecular Weight: 463.55

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.33%

99.33

Products Often Used Together with Berzosertib (VE-822)

Sacituzumab-govitecan

It and Sacituzumab Govitecan demonstrate anti-tumor activity in heavily pre-treatment tumors.

Related Targets	PI3K Akt mTOR AMPK GSK-3 DNA-PK PDPK1 PTEN PP2A PDK PI4K PIKfyve MELK
Related Products	KU-55933 VE-821 KU-60019 Ceralasertib (AZD6738) AZ20 AZD0156 Mirin AZD1390 CP-466722 Elimusertib (BAY-1895344) hydrochloride ETP-46464 Elimusertib (BAY-1895344) CGK 733 VX-803 (M4344) AZ31 AZ32 HAMNO Tuvusertib Cinobufagin Camonsertib (RP-3500) ATM Antibody [M23L2] Schisandrin B MSH6 Antibody [H6K16] Phospho-ATR (Ser428) Antibody [H24J12] STAG2 Antibody [L5L7] ATR Antibody [P23D7] Microcephalin-1/BRIT1 Antibody [N5J16] Lartesertib (M4076) ART0380 SKLB-197

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HCK1T-HPV16	Function Assay	0.5 nM	24 h	enhances E1-dependent replication of the HPV16 genome	25717108
HCK1T-HPV16	Function Assay	0.5 nM	24 h	increases the levels of E1	25717108
MDCK	Cytotoxicity assay	50 nM	72 h	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability at 50 nM pretreated for 72 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay	27823879
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	463.55	Formula	C₂₄H₂₅N₅O₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1232416-25-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	VX970, M6620			Smiles	CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N

Solubility

In vitro
Batch:

DMSO : 23 mg/mL (49.61 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 33 mg/mL (71.18 mM) Warmed with 50°C water bath; Ultrasonicated;
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG 300 2 5%Tween80 3 50% ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (2.16mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 450 μL PEG 300, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG 300 2 5%Tween80 3 50% ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.500mg/ml (3.24mM)	Taking the 1 mL working solution as an example, add 50 μL of 30 mg/mL clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween-80 to the above system, mix evenly to clarify it; then Continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features	The first ATR-targeted drug candidate with high selectivity for ATR.
Targets/IC₅₀/Ki	ATR ^[1] (HT29 cells) 19 nM
In vitro	Berzosertib (VE-822) at 80 nM attenuates the ATR signaling pathway and reduces survival in tumor cells in response to XRT and LY-188011. It also attenuates ATR signaling in normal cells without enhancing radiation and LY-188011 killing in such cells. This compound increases XRT-induced residual γH2AX and 53BP1 foci compared with XRT in MiaPaCa-2 and PSN-1 cells. Its pre-treatment decreases Rad51 foci after XRT in MiaPaCa-2 and PSN-1 cells. It alone increases the G1-phase-fraction in MiaPaCa-2 and PSN-1 cells, and abrogates XRT enriched G2/M-phase-fraction in these cells. VE-822 has little effect alone, while combined with XRT and/or LY-188011 it enhances early and late apoptosis in PSN-1 cells that is strongest in the triple combination. ^[1] It increases tumor response to DNA damaging agents associated with blockade of pChk1 Ser345. ^[2]
In vivo	Berzosertib (VE-822) at 60 mg/kg inhibits phospho-Ser-345-Chk1 in mice bearing PSN-1 tumors after DNA-damaging agents. Combined with XTR, it doubles the time for tumors to grow to 600 mm³ compared with XRT alone in mice bearing both PSN-1 and MiaPaCa-2 tumors. When added to the combination of LY-188011 and XRT, this compound substantially prolongs tumor growth delay compared with the Gem+XRT1 group in mice bearing PSN-1 tumors. Its combination with XRT1 increases uptake in tumors by 44% compared with XRT1, suggesting that addition of VE-822 increased γH2AX phosphorylation and persistence of DNA damage caused by XRT. ^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/23222511/ [2] https://pubmed.ncbi.nlm.nih.gov/23583268/

Applications

Methods	Biomarkers	PMID
Western blot	p-STAT3 / STAT3 / AKT / p-AKT p21 / caspase-3 / PARP / γ-H2AX PARP / RPA32 / γH2AX / H4 / MEK WEE1 / p-CDC25c / p-CDK1 / CDK1 / p-CDK2 / CDK2 / RRM1 / RRM2	29890208
Growth inhibition assay	Cell viability	31014753
Immunofluorescence	PD-L1 / Hsp90B1 γH2AX / p53	30094103

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02723864	Completed	Neoplasms	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	August 9 2017	Phase 1
NCT02487095	Active not recruiting	Carcinoma Non-Small -Cell Lung\|Ovarian Neoplasms\|Small Cell Lung Carcinoma\|Uterine Cervical Neoplasms\|Carcinoma Neuroendocrine\|Extrapulmonary Small Cell Cancer	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	July 30 2015	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to have information to prepare it for mouse gavage. Thank you for your answer.

Answer:
It can be dissolved in 1% CMC Na at 30mg/ml as a suspension for oral gavage.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):